LITAK 2 mg/ml solution for injection

DRUG2 trials

Sponsors

St. Anna Childrens Cancer Research Institute GmbH, Universita' Degli Studi Di Perugia

Conditions

Langerhans Cell HistiocytosisPreviously untreated patients with diagnosis of HCL

Phase 2

LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

Not yet recruitingCTIS2024-512676-36-00

St. Anna Childrens Cancer Research Institute GmbHLangerhans Cell Histiocytosis

Target: 1124Updated: 2024-10-14

VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEMIA (HCL): A PHASE-2 RANDOMIZED MULTICENTER TRIAL

RecruitingCTIS2024-520119-41-00

Universita' Degli Studi Di PerugiaPreviously untreated patients with diagnosis of HCL

Start: 2023-01-15Target: 120Updated: 2025-12-10